Professor Janet Brown

BMedSci, MBBS, MSc, MD, FRCP

School of Medicine and Population Health

Professor of Translational Medical Oncology

Chair in Medical Oncology

j.e.brown@sheffield.ac.uk
+44 114 226 5007

+44 114 226 5364 (Fax)

Weston Park Hospital

Full contact details

Professor Janet Brown
School of Medicine and Population Health
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

After graduating in Medicine from the University of Newcastle upon Tyne and appointment as a Clinical Lecturer in Oncology in Sheffield, followed by a first consultant appointment in Leeds, Janet was appointed to a Chair in Translational Medical Oncology in the University of Sheffield and as Honorary Consultant in Medical Oncology at the Sheffield NHS Foundation Trust in 2012. Her specialist areas of clinical practice are prostate, renal and breast cancers. Her patient-orientated, practice-changing research focuses on optimising skeletal health in cancer patients and innovative treatment pathways for urological cancers, including novel approaches to immunotherapy.

As a Clinician Scientist, Janet is passionate about the need for research-led improvements for the benefit of patients and is especially concerned to support and develop clinical academic training to nurture and support the clinical academics of the future. Through her appointment as the Director of Clinical Academic Training for South Yorkshire, she leads the organisation of clinical academic training for Academic Clinical Fellows and Clinical Lecturers across all medical specialties in the region. She has brought in a number of innovations, including the organisation of workshops and training for which the trainees themselves play a major role in developing the agenda under senior guidance, as well as championing closer working between medical, dental and allied health professions, nursing and midwifery early career academics.

Amongst a range of personal awards, she gained the American Society for Clinical Oncology Pain Merit Award in 2003 and the UK McElwain Research Prize for Medical Oncology in 2005. In 2008, she won a Cancer Research UK Clinician Scientist Fellowship for studies in bone oncology, which she held until 2014.

She has acquired a global reputation in the effects of cancer on bone and has been appointed as President of the International Cancer and Bone Society from July 2025. She is also currently Deputy Director (and Oncology Lead) of the Sheffield Mellanby Centre for Musculoskeletal Research.

Research interests

With more than 170 published, peer-reviewed research papers, Janet has had more than 50 successful grant applications in recent years and has recent and current research funding totalling over £15 million, with more than £10 million as Principal Investigator, from Cancer Research UK, National Institute for Health Research (NIHR), Yorkshire Cancer Research, Breast Cancer Campaign, Prostate Cancer UK, Weston Park Hospital Cancer Charity and other bodies.

As an academic leader and clinician scientist, Janet engages in both clinical and laboratory research, which is internationally recognised, with publications in Lancet, Journal of Clinical Oncology, Journal of the National Cancer Institute, Nature Clinical Oncology, Clinical Cancer Research, Annals of Oncology Breast Cancer Research and Treatment and other journals. Her patient-orientated, practice-changing research focuses on optimising skeletal health in cancer patients and innovative treatment pathways for urological cancers. She leads clinical bone oncology research in the University of Sheffield, which is recognised as a global leader in this field.

As National Chief Investigator (CI) on a large Phase III kidney cancer trial in 60 UK sites (£2.4M from NIHR), Janet and colleagues demonstrated that treatment breaks from tyrosine kinase inhibitor systemic cancer therapy improved patient quality of life and saved NHS costs without reducing survival (Lancet Oncology, 2023)- As a result of this published study, NHS England recommended a national practice change to allow such treatment breaks.

Janet has also recently embarked as lead on a £2.8 million digital health programme (E-IMMUNE), funded by the Yorkshire Cancer Research Pioneer scheme, to reduce the effects of immunotherapy toxicity by empowering patients and clinicians in the management of immunotherapy toxicity through a new digital care pathway.

In the most recent UK Research Excellence Framework (REF), Janet contributed five 4* papers and led a 4* Impact Case on Sheffield’s practice-changing adjuvant bisphosphonate (BP) trials, which now save 1,000 UK breast cancer lives and £50M annually.

Janet also leads the Clinical Bone Oncology and Biomarkers Group in the University of Sheffield, which has a particular focus on the impact of cancer on the skeleton in patients with breast, prostate and renal cancer. Recent research includes the use of biomarkers in established bone metastasis to aid patient management and studies of the negative impact of cancer treatments on bone health. One of the main objectives of their current clinical and laboratory work is to develop novel prognostic and predictive biomarkers for clinical use in patients with early cancer to help in prevention or delay of cancer metastasis to bone, after which disease is incurable.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R , Jones R et al (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24(3), 213-227.
Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI , Juarez P et al (2021) Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic : an international perspective and recommendations. Journal of Bone Oncology, 29. View this article in WRRO
D'Oronzo S, Wood S & Brown JE (2021) “The use of bisphosphonates to treat skeletal complications in solid tumours”. Bone, 147, 115907-115907.
D'Oronzo S, Gregory W, Nicholson S, Chong YK, Brown J & Coleman R (2021) Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 28. View this article in WRRO
Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A , MacPherson I et al (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial. Trials, 21(1). View this article in WRRO
Atala A (2019) Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis. Journal of Urology, 202(6), 1101-1101.
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt A, Kuemmel S , Ruiz I et al (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncology, 5(11), 1556-1564. View this article in WRRO
Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30), 1-328. View this article in WRRO
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
Probert C, Dottorini T, Speakman A, Hunt S, Nafee T, Fazeli A, Wood S, Brown JE & James V (2019) Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene, 38(-), 1751-1763. View this article in WRRO
Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva M , Dunning MJ et al (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of Pathology, 247(3), 381-391. View this article in WRRO
Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G , Maccon K et al (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. JNCI: Journal of the National Cancer Institute, 110(8), 871-879. View this article in WRRO
Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94, 70-78.
Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown J, Shore ND, Saad F, Spencer A, Zhu L & Warner DJ (2016) Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents. Clinical Cancer Research. View this article in WRRO
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C , Porfiri E et al (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.. Health Technol Assess, 20(53), 1-288. View this article in WRRO
James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O’Sullivan J , Parker C et al (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. JAMA Oncology, 2(4), 493-493. View this article in WRRO
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4), ---. View this article in WRRO
Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M , Damião R et al (2015) Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. European Urology, 68(1), 42-50.
Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer, 21(2), 327-341.
Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology.
Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, Milecki P, Wang H, Dansey RD & Goessl CD (2010) A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.. Journal of Clinical Oncology, 28(18_suppl), LBA4507-LBA4507.
Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). Journal of Clinical Oncology, 27(15_suppl), e16016-e16016.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J & Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.. J Natl Cancer Inst, 97(1), 59-69.
Wood SL & Brown JE () Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers, 12(8), 2109-2109.
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A , Cross W et al () Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer : long-term survival results from the STAMPEDE trial. Annals of Oncology, 1-12. View this article in WRRO

Chapters

Coleman RE, Brown J & Holen I (2020) Bone Metastases, Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier

Reports

Brown J (2022) Expert Panel: evaluation of the Government’s commitments in the area of cancer services in England View this article in WRRO

All publications

Journal articles

Gibson FG, Paggiosi MA, Handforth C, Brown JE, Li X, Dall'Ara E & Verbruggen SW (2025) Altered vertebral biomechanical properties in prostate cancer patients following androgen deprivation therapy. Bone, 195, 117465-117465.
Drudge-Coates L, Davey P, Murray J, Huang Q, Lopex-Guadamillas E & Brown J (2025) Management and mitigation of metabolic bone disease and cardiac adverse events throughout the prostate cancer pathway: clinical review and practical recommendations. Current Medical Research and Opinion.
Gharibzadeh S, Routen A, Razieh C, Zaccardi F, Lawson C, Gillies C, Heller S, Davies M, Atkins H, Bain SC , Lone NL et al (2025) Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study. eClinicalMedicine, 79. View this article in WRRO
Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C , Junker-Jensen A et al (2024) Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7), e009368-e009368.
Huang Q, Brown J & Mitchell C (2024) Assessment and management of fracture risk in men with prostate cancer taking androgen deprivation therapy: a retrospective observational primary care database study. British Journal of General Practice, 74(suppl 1), bjgp24X737637-bjgp24X737637.
Handforth C, Paggiosi MA, Jacques R, Gossiel F, Eastell R, Walsh JS & Brown JE (2024) The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: A longitudinal observational study (The ANTELOPE Study). Journal of Bone Oncology, 47. View this article in WRRO
Brown J, Santini D, Charnley N, Ogareva A, Chisholm A & Jones R (2024) Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review. Cancer Treatment Reviews, 102792-102792.
Jones C, Sachdeva A, Murphy L, Murray M, Brown L, McCloskey E, Atard G, Parmar M, James N, Sydes M , Clarke N et al (2024) #30. Fractures in metastatic hormone-sensitive prostate cancer (mHSPC). Results from two phase 3 trials from the STAMPEDE platform. Journal of Bone Oncology, 45, 100568-100568.
Wood SL, Lopez-Guajardo A, Oliva M, Collins M, Clézardin P, Croset M & Brown JE (2024) #32. Identification of proteins regulating the metastatic spread of breast cancer to bone: Proteomic analysis of the role of the pro-metastatic transcription factor TWIST1 and the gene target micro-RNA (miR-10b). Journal of Bone Oncology, 45, 100570-100570.
Wood SL, Lopez-Guajardo A, Oliva MR, Collins M, Pham K, Dunning M, Chambers EV & Brown JE (2024) #28. Identification of key proteins within prostate cancer derived exosomes and their role in priming the pre-metastatic niche. Journal of Bone Oncology, 45, 100566-100566.
Brown J, Paggiosi M, Rathbone E, Dodwell D, Cameron D, Gregory W, Eastell R & Coleman R (2024) BoHFAB. The impact of adjuvant zoledronate therapy on bone health in postmenopausal patients with early breast cancer. Journal of Bone Oncology, 45, 100529-100529.
Jones C, Gray S, Brown M, Brown J, McCloskey E, Rai BP, Clarke N & Sachdeva A (2024) Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials. European Urology Oncology.
Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, Griffiths R, Sharma A, Katona E, Howard H , Velikova G et al (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).. J Clin Oncol, JCO2300236.
Jones C, Dutey-Magni P, Murphy LR, Murray M, Brown JE, McCloskey E, Parmar MK, James ND, Sydes MR, Brown LC , Clarke NW et al (2023) 1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons. Annals of Oncology, 34, S956-S957.
Huang Q, Grossett V, Daley S, Fryer K, Brown J & Mitchell C (2023) Engagement with a local African-Caribbean community to explore perspectives and research priorities among Black men for prostate cancer using a co-participatory approach. British Journal of General Practice, 73(suppl 1), bjgp23X733797-bjgp23X733797.
Mitchell C, Fryer K, Guess N, Aminu H, Jackson B, Gordon A, Reynolds J, Huang Q, Jayasooriya S, Mawson R , Lawy T et al (2023) Underserved ‘Deep End’ populations: a critical analysis addressing the power imbalance in research. British Journal of General Practice, 73(732), 326-329.
Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R , Jones R et al (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24(3), 213-227.
Challapalli A, Ratnayake G, McGrane J, Frazer R, Gupta S, Parslow DS, Kingdon SJ, Lydon A, Sharma A, Tuthill M , McCusker C et al (2022) 1463P Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review. Annals of Oncology, 33, S1215-S1215.
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442-100442.
Brown JE & Symeonides SN (2022) Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma.. Eur Urol.
Wood S, Lopez-Guajardo A, Oliva M & Brown J (2022) Identification of proteins which regulate the metastatic spread of breast cancer downstream of TWIST1. Bone Reports, 16, 101362-101362.
Wood S, Lopez A, Oliva M & Brown J (2022) Identification of osteoblast proteins which are regulated by prostate cancer derived exosomal micro-RNAs. Bone Reports, 16, 101363-101363.
Lovero D, D’Oronzo S, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C, Lauricella E, Coleman R & Silvestris F (2022) Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 126(3), 419-429.
Porter I, Theodoulou E, Holen I, Harper-Wynne C, Baron-Hay S, Wilson C & Brown J (2021) Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience. Journal of Bone Oncology, 31, 100402-100402.
Andrews RE, Brown JE, Lawson MA & Chantry AD (2021) Myeloma bone disease : the osteoblast in the spotlight. Journal of Clinical Medicine, 10(17). View this article in WRRO
Brown JE, Royle K-L, Ralph C, Meads D, Martin A, Howard H, Linsley C, Swain J, Powles TB, Jones R , Eisen T et al (2021) LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). Annals of Oncology, 32, S1303-S1304.
Brown JE, Harrow B, Marciniak A, McCarthy C, Cirneanu L & Protheroe A (2021) 680P Cabozantinib and axitinib after VEGF therapy in patients with aRCC: A retrospective cohort study. Annals of Oncology, 32, S701-S701.
Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell TS, Fife K, Griffiths R, Sharma A, Katona E, Howard H , Velikova G et al (2021) LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). Annals of Oncology, 32, S1304-S1305.
Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI , Juarez P et al (2021) Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic : an international perspective and recommendations. Journal of Bone Oncology, 29. View this article in WRRO
Reale S, Turner RR, Sutton E, Steed L, Taylor SJC, Morrissey D, Doherty P, Greenfield DM, Collinson M, Hewison J , Brown J et al (2021) Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care : a feasibility and acceptability study (the STAMINA trial). Scientific Reports, 11(1). View this article in WRRO
D'Oronzo S, Wood S & Brown JE (2021) “The use of bisphosphonates to treat skeletal complications in solid tumours”. Bone, 147, 115907-115907.
D'Oronzo S, Gregory W, Nicholson S, Chong YK, Brown J & Coleman R (2021) Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 28. View this article in WRRO
D'oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C & Silvestris F (2021) Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases. Bone Reports, 14, 100840-100840.
Turner RR, Arden MA, Reale S, Sutton E, Taylor SJC, Bourke L, Greenfield DM, Morrissey D, Brown J, Doherty P , Rosario DJ et al (2021) The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial. BMC Health Services Research, 21. View this article in WRRO
Reale S, Turner RR, Sutton E, Taylor SJC, Bourke L, Morrissey D, Brown J, Rosario DJ & Steed L (2021) Towards implementing exercise into the prostate cancer care pathway : development of a theory and evidence-based intervention to train community-based exercise professionals to support change in patient exercise behaviour (The STAMINA trial). BMC Health Services Research, 21(1). View this article in WRRO
Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) Abstract PS14-02: A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. Cancer Research, 81(4_Supplement).
Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2021) Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, 20(3), 589-601.
Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE & Greenfield DM (2021) Correction to: Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer, 29(2), 1145-1145.
Levy DT, Sánchez‐Romero LM, Li Y, Yuan Z, Travis N, Jarvis MJ, Brown J & McNeill A (2021) England SimSmoke: the impact of nicotine vaping on smoking prevalence and smoking‐attributable deaths in England. Addiction, 116(5), 1196-1211.
Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A , MacPherson I et al (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial. Trials, 21(1). View this article in WRRO
Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, Davis ID, Stockler MR, Albiges L, Escudier B , Larkin J et al (2020) Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 38(34), 4064-4075. View this article in WRRO
Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C , Collinson FJ et al (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. View this article in WRRO
Rossi SH, Blick C, Handforth C, Brown JE & Stewart GD (2020) Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. European Urology Focus, 6(5), 991-998.
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A , Fife K et al (2020) Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 6(5), 999-1005.
D'Oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Cives M, Tucci MG, Stucci LS, Coleman RE & Silvestris F (2020) 30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients. Annals of Oncology, 31, S26-S26.
Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Abstracts: 2019 San Antonio Breast Cancer Symposium.
Atala A (2019) Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis. Journal of Urology, 202(6), 1101-1101.
A M El Badri S, Salawu A & Brown JE (2019) Bone Health in Men with Prostate Cancer: Review Article. Current Osteoporosis Reports, 17(6), 527-537.
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt A, Kuemmel S , Ruiz I et al (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncology, 5(11), 1556-1564. View this article in WRRO
Brown JE, Westbrook JA & Wood SL (2019) Dedicator of cytokinesis 4 : a potential prognostic and predictive biomarker within the metastatic spread of breast cancer to bone. Cancer Informatics, 18, 1-3. View this article in WRRO
Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30), 1-328. View this article in WRRO
Rossi SH, Fielding A, Blick C, Handforth C, Brown JE & Stewart GD (2019) Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care. European Urology, 75(6), 891-893. View this article in WRRO
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
D'Oronzo S, Coleman R, Brown J & Silvestris F (2019) Metastatic bone disease: pathogenesis and therapeutic options. Journal of Bone Oncology, 15. View this article in WRRO
Probert C, Dottorini T, Speakman A, Hunt S, Nafee T, Fazeli A, Wood S, Brown JE & James V (2019) Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene, 38(-), 1751-1763. View this article in WRRO
Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva M , Dunning MJ et al (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of Pathology, 247(3), 381-391. View this article in WRRO
Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE & Greenfield DM (2019) Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer, 27(5), 1755-1763. View this article in WRRO
Brown JE & Wood SL (2018) Novel mediators of breast cancer bone metastasis—insights from studies of gene-regulation and the global proteome. Annals of Translational Medicine, 6(S1), S71-S71.
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13, 123-135. View this article in WRRO
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Research, 78(18), 5300-5314. View this article in WRRO
Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G , Maccon K et al (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. JNCI: Journal of the National Cancer Institute, 110(8), 871-879. View this article in WRRO
Greasley RU, Turner R, Collins K, Brown J, Bourke L & Rosario DJ (2018) Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems. BMC Cancer, 18(1). View this article in WRRO
Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94, 70-78.
Handforth C, D’Oronzo S, Coleman R & Brown J (2018) Cancer Treatment and Bone Health. Calcified Tissue International, 102(2), 251-264. View this article in WRRO
D’Oronzo S, Brown J & Coleman R (2017) The role of biomarkers in the management of bone-homing malignancies. Journal of Bone Oncology, 9, 1-9. View this article in WRRO
Zekri J, Marples M, Taylor D, Kandukurti K, McParland L & Brown JE (2017) Complications of bone metastases from malignant melanoma. Journal of Bone Oncology, 8, 13-17. View this article in WRRO
Kelly-Morland C, Zhong J, Goh V, Wah T, Ralph C, Thistlethwaite F, Patel P, Nathan P, Eisen T, Gregory W , McParland L et al (2017) Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial. Annals of Oncology, 28, v315-v315.
D'Oronzo S, Brown J & Coleman R (2017) The value of biomarkers in bone metastasis. European Journal of Cancer Care.
Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown J, Shore ND, Saad F, Spencer A, Zhu L & Warner DJ (2016) Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients With Advanced Cancer and Bone Metastases Treated With Bone Antiresorptive Agents. Clinical Cancer Research. View this article in WRRO
GBD 2015 Mortality and Causes of Death Collaborators (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388(10053), 1459-1544. View this article in WRRO
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C , Porfiri E et al (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.. Health Technol Assess, 20(53), 1-288. View this article in WRRO
GlobalSurg Collaborative (2016) Mortality of emergency abdominal surgery in high-, middle- and low-income countries. British Journal of Surgery, 103(8), 971-988.
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C , Porfiri E et al (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. View this article in WRRO
Orsini L, Gilbert D, Podicheti R, Jansen M, Brown JB, Solari OS, Spanier KI, Colbourne JK, Rush D, Decaestecker E , Asselman J et al (2016) Daphnia magna transcriptome by RNA-Seq across 12 environmental stressors. Scientific Data, 3. View this article in WRRO
Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D, Rini BI, Staehler MD , Ravaud A et al (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 34(14), 1660-1668. View this article in WRRO
Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bhal A, Fife K , Webb A et al (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27(5), 880-886. View this article in WRRO
ATLAS Collaboration (2016) Performance of b -jet identification in the ATLAS experiment. Journal of Instrumentation, 11(04), P04008-P04008. View this article in WRRO
James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O’Sullivan J , Parker C et al (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. JAMA Oncology, 2(4), 493-493. View this article in WRRO
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4), ---. View this article in WRRO
von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS , Marx G et al (2016) Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive Care in Cancer, 24(3), 1327-1337. View this article in WRRO
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K , Shore N et al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive Care in Cancer, 24(1), 447-455. View this article in WRRO
Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE , Saad F et al (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. European Journal of Cancer, 53, 75-83. View this article in WRRO
Wagstaff J, Jones R, Hawkins R, Porfiri E, Pickering L, Bahl A, Brown J & Buchan S (2016) Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of Oncology, 27(1), 159-165. View this article in WRRO
Stopeck AT, Fizazi K, Body J-J, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K , Shore N et al (2016) Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive Care in Cancer, 24(1), 457-458.
Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M , Damião R et al (2015) Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. European Urology, 68(1), 42-50.
Shore N, Smith MR, Lipton A, Brown JE, Oudard S, Carducci M, Saad F, Damiao R, Zhu L, Warner D & Fizazi K (2015) MP73-10 BONE TURNOVER MARKER LEVELS AND OUTCOMES IN MEN WITH PROSTATE CANCER AND BONE METASTASES TREATED WITH BONE ANTIRESORPTIVE AGENTS. Journal of Urology, 193(4S).
Westbrook JA, Noirel J, Brown JE, Wright PC & Evans CA (2015) Quantitation with chemical tagging reagents in biomarker studies. PROTEOMICS - Clinical Applications, 9(3-4), 295-300.
Brown JE & Wood SL (2014) Assessment of the Impact of Targeted Therapy on Metastatic Bone Disease in Renal Cancer. European Urology, 66(3), 510-511.
von Moos R, Body J-J, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL , Palazzo FG et al (2014) Erratum to: Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 22(8), 2309-2310.
Brown J, WOOD SL & WESTBROOK JA (2014) Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment..
Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer, 21(2), 327-341.
Brown JE, Zeng L & Wilson C (2014) Bone Biomarkers in Research and Clinical Practice, 95-124.
Palmieri C, Fullarton JR & Brown J (2013) Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis. Clinical Cancer Research, 19(24), 6863-6872.
Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, Braun A, Van Brunt K & McDaniel K (2013) Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Preference and Adherence, 7, 855-865. View this article in WRRO
von Moos R, Body J-J, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL , Palazzo FG et al (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 21(12), 3497-3507.
Wood SL, Westbrook JA & Brown JE (2013) Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment. Cancer Treatment Reviews.
Ganju V, Costa L, Fizazi K, Saad F, Brown J, von Moos R, Oudard S, Sternberg CN, Miller K, Wang H , Maniar T et al (2013) Denosumab and zoledronic acid (ZA) treatment in patients with genitourinary (GU) cancers and bone metastases. BJU INTERNATIONAL, 112, 11-11.
Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R , Jyothirmayi R et al (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).. J Clin Oncol, 31(21), 2685-2691.
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. Journal of Clinical Oncology, 31(18_suppl), LBA5000-LBA5000.
Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N , Smith M et al (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features - An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2(2), 70-76. View this article in WRRO
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. Journal of Clinical Oncology, 31(15_suppl), lba5000-lba5000.
Coleman RE, Rathbone E & Brown JE (2013) Management of cancer treatment-induced bone loss.. Nat Rev Rheumatol, 9(6), 365-374.
Karim SM, Brown J & Zekri J (2013) Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers. Clinical Advances in Hematology and Oncology, 11(5), 281-287.
Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D & Bell R (2012) Abstract S6-4: Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study.. General Session Abstracts.
Lipton A, Cook R, Brown J, Coleman R, Body JJ & Smith M (2012) Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses. Clinical Oncology.
Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D, Tubeuf S, Hanlon P, McParland L, Wah T , Selby PJ et al (2012) The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer. BMC CANCER, 12. View this article in WRRO
Richardson G, Body J-J, von Moos R, Saad F, Brown J, Lipton A, Fizazi K, Ying W, Goessl C & Richhariya A (2012) HEALTH RESOURCE UTILISATION (HRU) AND PATIENT BURDEN ASSOCIATED WITH SKELETAL-RELATED EVENTS (SRES) IN A RANDOMISED CONTROLLED TRIAL SETTING. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 8, 354-354.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M , Bilynskyy B et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. EUROPEAN JOURNAL OF CANCER, 48(16), 3082-3092.
Brown JE, Cook RJ, Lipton A & Coleman RE (2012) Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.. Clin Cancer Res, 18(22), 6348-6355.
Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM & Coleman RE (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology, 1(2), 57-62. View this article in WRRO
Fizazi K, Brown JE, Carducci M, Shore ND, Sieber P, Kueppers F, Karsh L, Wei R & Goessl C (2012) Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 Study. Annals of Oncology, 23, ix309-ix309.
Wood SL & Brown JE (2012) Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treatment Reviews, 38(4), 284-291.
Matza LS, Cong Z, Chung K, Stopeck A, Tonkin KS, Brown JE, Braun AH, Van Brunt K & McDaniel K (2012) Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases.. Journal of Clinical Oncology, 30(15_suppl), e16528-e16528.
Woodward EJ & Brown JE (2012) Denosumab in the treatment of bone metastases. Clinical Investigation, 2(5), 519-526.
Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology.
Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology, 9(2), 110-118.
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH , Barrios CH et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology, 23(5), 1341-1347.
Coleman R, Woodward E, Turner L, Marshall H, Collinson M, Dodwell D, Davies C, Bell R, Cameron D & Brown J (2011) P2-19-01: Impact of Zoledronic Acid on Fractures, Bone Mineral Density and Bone Remodeling in the AZURE Trial (BIG 01–04).. Poster Session Abstracts.
Collinson F, Brown J, McCabe C, Brown J, Tubeuf S, Potrata B, Hewison J, Rombach I, Selby P, Olivier C , Howard H et al (2011) The STAR trial: can quality of life benefit offset any survival detriment?. Trials, 12(S1).
Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body J-J, Smith M , Lee K-A et al (2011) Consensus on the utility of bone markers in the malignant bone disease setting.. Crit Rev Oncol Hematol, 80(3), 411-432.
Martin M, Kearney M, Bracco A & Brown J (2011) AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM. VALUE IN HEALTH, 14(3), A158-A158.
Cure S, Martin M, Bracco A, Brown J & Kearney M (2011) AN EPIDEMIOLOGICAL MODEL OF PROSTATE CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM. VALUE IN HEALTH, 14(3), A158-A158.
Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.. Breast Cancer Res Treat, 127(2), 429-438. View this article in WRRO
Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H , Jiang Q et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. LANCET, 377(9768), 813-822.
Brown JE, Cleeland CS, Fallowfield LJ, Patrick DL, Fizazi K, Smith MR, Maroto JP, Michel MS, Feng A, Goessl C & Chung K (2011) PAIN OUTCOMES IN PATIENTS WITH BONE METASTASES FROM CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 TRIAL OF DENOSUMAB VS. ZOLEDRONIC ACID. EUROPEAN UROLOGY SUPPLEMENTS, 10(2), 336-336.
Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P & Brown J (2011) Skeletal complications and survival in renal cancer patients with bone metastases.. Bone, 48(1), 160-166.
Collinson FJ, Vasudev NS, Berkin L, Khan MM, Selby PJ & Brown JE (2011) Sunitinib-induced severe hypothyroidism with cardiac compromise. Medical Oncology, 28(SUPPL. 1).
Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E & Brown J (2011) Zoledronic acid.. Expert Opin Drug Saf, 10(1), 133-145.
Schmidt H, Brown J, Mouritzen U, Selby P, Fode K, Svane IM, Cook GP, Mollerup DH & Geertsen PF (2010) Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: A phase I trial. Clinical Cancer Research, 16(21), 5312-5319.
Vasudev NS & Brown JE (2010) Medical management of metastatic bone disease. Current Opinion in Supportive and Palliative Care, 4(3), 189-194.
Brown JE, Sherriff JM & James ND (2010) Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem. BJU INTERNATIONAL, 106(5), 726-727.
Brown JE, Sherriff JM & James ND (2010) Reply. BJU International, 106(5), 727.
Cameron DA, Douglas S, Brown JE & Anderson RA (2010) Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: Is it dependent on oestrogen deficiency?. Breast Cancer Research and Treatment, 123(3), 805-814.
Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, Milecki P, Wang H, Dansey RD & Goessl CD (2010) A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.. J Clin Oncol, 28(18_suppl), LBA4507.
Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, Milecki P, Wang H, Dansey RD & Goessl CD (2010) A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.. Journal of Clinical Oncology, 28(18_suppl), LBA4507-LBA4507.
Brown JE, Sherriff JM & James ND (2010) Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: An increasing, but under-recognized problem. BJU International, 105(8), 1042-1043.
Brown JE & Coleman RE (2010) Biomarkers of bone turnover in oncology: Applications in diagnosis and treatment. Expert Opinion on Medical Diagnostics, 4(2), 125-138.
Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP & Coleman RE (2010) The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.. Bone, 46(3), 801-805.
Sherriff JM, Brown JE & James ND (2010) An under-recognised risk. BMJ (Online), 340(7738), 118.
Brown JE & Sim S (2010) Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia, 12(9), 685-696.
Brown JE, Cook RJ, Lipton A, Costa L & Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 1-13.
Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). Journal of Clinical Oncology, 27(15_suppl), e16016-e16016.
Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R & Major P (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.. Cancer Treat Rev, 34(7), 629-639.
Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.. Clin Cancer Res, 14(19), 6336-6342.
Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE & Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. CANCER, 113(1), 193-201.
Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP.. J Clin Oncol, 26(15_suppl), 19003.
Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study.. J Clin Oncol, 26(15_suppl), 554.
Hall PS, Kancherla K, Sastry PSRK & Brown JE (2008) Severe epistaxis with tyrosine kinase inhibitors. CLINICAL ONCOLOGY, 20(4), 318-319.
Vasudev NS, Brown JE, Brown SR, Rafiq R, Morgan R, Patel PM, O'Donnell D, Harnden P, Rogers M, Cocks K , Anderson K et al (2008) Prognostic factors in renal cell carcinoma: Association of preoperative sodium concentrationwith survival. Clinical Cancer Research, 14(6), 1775-1781.
Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE & Coleman RE (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J THORAC ONCOL, 3(3), 228-236.
Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) OC5. Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the ARIBON study. Cancer Treatment Reviews, 34, 51-52.
Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R & Coleman RE (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.. Calcif Tissue Int, 81(5), 341-351.
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O-P, McCloskey E & Coleman RE (2007) Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.. Clin Cancer Res, 13(18 Pt 1), 5406-5410.
Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) Normalization of bone markers and improved survival during zoledronic acid therapy. Journal of Clinical Oncology, 25(18_suppl), 9013-9013.
Vasudev NS, Brown JE, Brown SR, Cocks K, O'Donnell D, Patel PM, Harnden P, Banks RE & Selby PJ (2007) Preoperative sodium concentration as a possible predictor of survival in patients with renal cell carcinoma. Journal of Clinical Oncology, 25(18_suppl), 10601-10601.
Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. Journal of Clinical Oncology, 25(18_suppl), 553-553.
Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ & Saad F (2007) Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. UROLOGY, 70(2), 315-319.
Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ & Coleman RE (2006) Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.. Clin Cancer Res, 12(21), 6480-6486.
Saad F, Coleman RE, Cook R, Smith MR, Brown JE, Hei JY & Chen YM (2006) Predictors of clinical outcome in patients with bone metastases from prostate cancer. Journal of Clinical Oncology, 24(18_suppl), 4555-4555.
Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F & Smith MR (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. CLIN CANCER RES, 12(11), 3361-3367.
Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A , Caraglia M et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. ONCOL REP, 15(5), 1351-1357.
Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, Eiser C, Coleman RE & Ross RJ (2006) High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.. Br J Cancer, 94(4), 469-472. View this article in WRRO
Hashemizadeh SA, Wells JPR, Murzyn P, Brown J, Jones BD, Wang T, Parbrook PJ, Fox AM, Mowbray DJ & Skolnick MS (2005) Picosecond carrier dynamics in AllnGaN multiple quantum wells. APPL PHYS LETT, 87(23).
Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J & Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.. J Clin Oncol, 23(22), 4925-4935.
Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O-P, Hancock B & Coleman R (2005) Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. Journal of Clinical Oncology, 23(16_suppl), 8023-8023.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J & Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.. J Natl Cancer Inst, 97(1), 59-69.
Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
Brown JE & Coleman RE (2004) Metastatic Bone Disease. American Journal of Cancer, 3(4), 265-265.
Brown JE, Neville-Webbe H & Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers.. Endocr Relat Cancer, 11(2), 207-224.
Galasko CSB (2004) Metastatic Bone Disease. American Journal of Cancer, 3(4), 265-265.
Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP & Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease.. Br J Cancer, 89(11), 2031-2037. View this article in WRRO
Brown JE & Coleman RE (2003) Metastatic Bone Disease. American Journal of Cancer, 2(4), 269-281.
Brown JE, Hatton MQ, Melchers R, Goldstraw P & Coleman RE (2003) Chemotherapy, erythropoietin and bloodless surgery in a Jehovah's Witness.. Clin Oncol (R Coll Radiol), 15(7), 371-377.
Brown JE & Coleman RE (2002) The present and future role of bisphosphonates in the management of patients with breast cancer.. Breast Cancer Res, 4(1), 24-29. View this article in WRRO
Brown JE & Coleman RE (2002) Assessment of the effects of breast cancer on bone and the response to therapy.. Breast, 11(5), 375-385.
Brown JE, Olujohungbe A, Chang J, Ryder WDJ, Morganstern GR, Chopra R & Scarffe JH (2000) All-Trans Retinoic Acid (Atra) and Tranexamic Acid: A Potentially Fatal Combination In Acute Promyelocytic Leukaemia. British Journal of Haematology, 110(4), 1010-1012.
Brown J & McIllmurray M (2000) Career focus on medical oncology. BMJ, 11, 2-3.
Brown J (2000) Cancer Genetics: Friend or foe of the junior doctor. Morecambe Bay Medical Journal, 8, 272-272.
Brown J (2000) Photodynamic therapy, its impact in clinical practice. Photodynamics, 3(2), 2-5.
Brown JE, Brown SB & Vernon DI (1999) Photosensitising drugs - Their potential in oncology. Expert Opinion on Investigational Drugs, 8(12), 1967-1979.
Brown JE, Brown SB & Vernon DI (1999) Photodynamic therapy - new light on cancer treatment. JOURNAL OF THE SOCIETY OF DYERS AND COLOURISTS, 115(9), 249-253.
Petruk N, Wood SL, Gregory W, Lopez-Guajardo A, Oliva M, Mella M, Sandholm J, Jukkola A, Brown JE & Selander KS () Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use. Scientific Reports, 15(1).
Leigh J, Lee SF, Fawaz A, Jia J, Theriau CF, Rodrigues J, Brown J & Ng TL () Assessment of the benefits of bone modifying agents in the management of advanced breast, prostate, and lung cancers. Current Opinion in Supportive & Palliative Care.
Huang Q, Mitchell C, Theodoulou E, Lee ACK & Brown J () Implementation of fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework. Journal of Cancer Survivorship.
Collinson F, Royle K-L, Swain J, Ralph C, Maraveyas A, Eisen T, Nathan P, Jones R, Meads D, Min Wah T , Martin A et al () Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment, 1-171.
Culliford R, Lawrence SED, Mills C, Tippu Z, Chubb D, Cornish AJ, Browning L, Kinnersley B, Bentham R, Sud A , Pallikonda H et al () Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma. Nature Communications, 15(1).
Evans H, Andrews R, Abedi FA, Sprules A, Trend J, Lovric G, Green A, Chantry A, Clarkin C, Brown J & Lawson M () Evidence for peri-lacunar remodeling and altered osteocyte lacuno-canalicular network in mouse models of myeloma-induced bone disease. JBMR Plus.
McNaught E, Reale S, Bourke L, Brown JE, Collinson M, Day F, Hewison J, Farrin AJ, Ibeggazene S, Innes AQ , Mason E et al () Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy (STAMINA): study protocol for a randomised controlled trial of the clinical and cost-effectiveness of the STAMINA lifestyle intervention compared with optimised usual care, including internal pilot and parallel process evaluation. Trials, 25(1).
Brown J, Harrow B, Marciniak A, McCarthy C, Houchard A, Cirneanu L & Protheroe A () Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England. Drugs - Real World Outcomes.
Brown J, Paggiosi MA, Rathbone E, Gregory W, Bertelli G, Din O, McCloskey E, Dodwell D, Cameron D, Eastell R & Coleman R () Adjuvant bisphosphonate therapy and bone health. Journal of Bone and Mineral Research.
Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A & Lewis CE () Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse. Frontiers in Immunology, 14.
Conroy S, Catto JWF, Bex A, Brown J, Cartledge J, Fielding A, Jones RJ, Khoo V, Nicol D, Stewart GD , Sullivan M et al () Diagnosis, treatment, and survival from kidney cancer: real‐world NHS England data between 2013‐2019. BJU International.
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I () The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo. Cancers, 15(8), 2211-2211.
Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
Brown JE () Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?. JAMA Oncology.
Zhong J, Palkhi E, Buckley DL, Collinson FJ, Ralph C, Jagdev S, Vasudev NS, Swain J, Brown JE & Wah TM () Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics, 11(7), 1302-1302.
Wood SL & Brown JE () Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers, 12(8), 2109-2109.
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A , Cross W et al () Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer : long-term survival results from the STAMPEDE trial. Annals of Oncology, 1-12. View this article in WRRO
Bourke L, Turner R, Greasley R, Sutton E, Steed L, Smith D, Brown J, Kelly B, Hulme C, Greenfield D , Persad R et al () A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS. PLOS ONE, 13(7), e0197606-e0197606. View this article in WRRO

Chapters

Wood S, Arikrishnan A, D’Oronzo S & Brown J (2025) Bone metastases; clinical aspects, Reference Module in Biomedical Sciences Elsevier
Wyld L, Cutress R & Morgan J (2024) Long-Term Effects of Anastrozole on Bone Mineral Density: 7-Year Results from the ATAC Trial, 50 Landmark Papers every Breast Surgeon Should Know (pp. 243-248). CRC Press
Wyld L, Cutress R & Morgan J (2024) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy: CREATE-X, 50 Landmark Papers every Breast Surgeon Should Know (pp. 165-170). CRC Press
Wyld L, Cutress R & Morgan J (2024) Adjuvant Zoledronic Acid in Patients with Early Breast Cancer: Final Efficacy Analysis of the AZURE (BIG 01/04) Randomised Open-Label Phase 3 Trial, 50 Landmark Papers every Breast Surgeon Should Know (pp. 237-242). CRC Press
Wyld L, Cutress R & Morgan J (2024) Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome among 100,000 Women in 123 Randomised Trials, 50 Landmark Papers every Breast Surgeon Should Know (pp. 159-164). CRC Press
Wood SL, Lopez-Guajardo A & Brown JE (2022) Identification of new therapeutic targets of bone cancers by proteomic strategies, Bone Cancer (pp. 783-803). Elsevier
Arias-Pinilla GA & Brown J (2022) The effects of anticancer therapies on bone metastases in breast cancer, Bone Cancer (pp. 987-1002). Elsevier View this article in WRRO
Brown J, Wood S & Lopez A (2021) Identification of new therapeutic targets of bone cancers by proteomic strategies In Heymann D (Ed.), Bone Cancer Bone Sarcomas and Bone Metastases - From Bench to Bedside (pp. 783-803). Elsevier View this article in WRRO
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Bone metastases
Coleman RE, Brown J & Holen I (2020) Bone Metastases, Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier
Hossain M, Pezaro C, Walsh J, Rathbone E & Brown J (2019) Metabolic complications In Young A, Board R, Leonard P, Cooksley T, Stewart A & Michie C (Ed.), Problem solving in acute oncology (pp. 84-88). ebn Health View this article in WRRO
Abdelhay E, Adiseshaiah PP, Aglietta M, Allègra M, Ascierto PA, Bastus NC, Basudan A, Berghuis AMS, Biasco G, Binato R , Borah A et al (2019) List of Contributors, Oncogenomics (pp. xv-xx). Elsevier
Schoon JJ, Wood SL & Brown JE (2019) TKIs in Renal Cell Carcinoma, Oncogenomics (pp. 551-563). Elsevier
Brown J, Wood S, Salawu A, Kroening H & D'Oronzo S (2019) Bone Metastases; Clinical Aspects In Martini L & Huhtaniemi I (Ed.), Encyclopedia of Endocrine Diseases (pp. 310-319). Oxford: Elsevier. View this article in WRRO
Wood S, Salawu A, Kroening H, D’Oronzo S & Brown J (2019) Bone Metastases; Clinical Aspects, Encyclopedia of Endocrine Diseases (pp. 310-319). Elsevier
Handforth C, D'Oronzo S & Brown J (2018) Medical Prevention and Treatment of Bone Metastases (pp. 799-808). Wiley View this article in WRRO
Schoon JJ, Wood SL & Brown JE (2018) TKIs in renal cell carcinoma: What can we expect in the future?, Oncogenomics: From Basic Research to Precision Medicine (pp. 551-563). View this article in WRRO
Kwan A & Brown JE (2018) Bone Health in Patients with Breast Cancer, Breast Cancer Management for Surgeons (pp. 673-679). Springer International Publishing
Salawu AT, Handforth C & Brown JE (2017) Bone-Targeted Therapies in Prostate Cancer, Management of Prostate Cancer (pp. 343-356). Springer International Publishing
Brown J (2014) Bone Biomarkers in Research and Clinical Practice In Vassiliou V, Chow E & Kardamakis D (Ed.), Bone Metastases A translational and Clinical Approach (pp. 95-124). Springer Netherlands
Wood SL & Brown JE (2014) The Application of ‘Omics’ Techniques for Cancers That Metastasise to Bone: From Biological Mechanism to Biomarkers In Vassiliou V, Chow E & Kardamakis D (Ed.), Bone Metastases (pp. 125-153). Springer Netherlands
Rathbone E, Brown J & Walsh J (2013) Metabolic Complications In Marshall E, Clark P, Selby P & Young A (Ed.), Problem Solving in Acute Oncology Clinical Publishing
Brown J & von Poznak C (2010) Expert Commentary for Breast Disease. In - (Ed.), A Year Book Quarterly 21 (pp. 1-1).
Brown JE & Chow E (2009) Bone Biomarkers in Research and Clinical Practice, Bone Metastases (pp. 93-116). Springer Netherlands
Brown J, Brown SB, Brown S & Vernon DI (1999) The role of photodynamic therapy in cancer treatment opportunities and limitations In Griffiths J (Ed.), Colour science Volume (pp. 200-210).
Coleman RE & Brown JE () Monitoring Response to Treatment-the Role of Biochemical Markers, Textbook of Bone Metastases (pp. 105-121). John Wiley & Sons, Ltd

Conference proceedings papers

Manickavasagar T, Kelly-Morland C, Wah TM, Nathan P, Brown J & Goh V (2024) Enhancement and Size-based Response Criteria for Evaluating Tyrosine Kinase Inhibitor Dosing Strategy in Metastatic Renal Cancer: Prospective Imaging Study from the UK STAR Trial. CLINICAL ONCOLOGY, Vol. 36(1) (pp E78-E79)
Jones C, Dutey-Magni P, Murphy L, Murray M, Brown J, Mccloskey E, Parmar MKB, Parker C, Attard G, James ND , Sydes MR et al (2024) Fracture-related hospitalisations in de novo advanced or metastatic hormonesensitive prostate cancer: Secondary analysis of the STAMPEDE abiraterone acetate plus prednisone plus /- enzalutamide and M1|RT phase 3 trials using health systems data. EUROPEAN UROLOGY, Vol. 85 (pp S1583-S1583)
Brown JE (2024) THE IMPACT OF ANDROGEN DEPRIVATION THERAPY ON BONE HEALTH IN PATIENTS WITH PROSTATE CANCER. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 36 (pp S77-S77)
Jones C, Gray S, Brown M, Brown J, Mc CE, Rai B, Clarke N & Sachdeva A (2023) Fracture and fall risk in men with advanced or metastatic prostate cancer treated with novel androgen receptor signalling inhibitors: A systematic review and meta-analysis of randomised controlled trials. EUROPEAN UROLOGY, Vol. 83
Jones C, Sachdeva A, Murphy L, Murray M, Brown L, Brown J, Mc CE, Attard G, Parmar M, James N , Sydes MR et al (2023) Clinical fracture incidence in metastatic hormone-sensitive prostate cancer and risk-reduction following addition of zoledronic acid to androgen deprivation therapy with or without docetaxel: Long-term results from the STAMPEDE trial. EUROPEAN UROLOGY, Vol. 83
Lefley D, Jones C, Danson S, Bryant H, Collis S, Brown J & Ottewell P (2023) Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
Pinto Marin A, Trilla L, Miranda J, Vasudev NS, García E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo-Fernández A , Lumbreras Herrera MI et al (2022) 1473P A prognostic microRNA-based signature for relapse risk prediction and definition of therapeutic targets in patients with high-risk localized clear cell renal cell carcinoma. Annals of Oncology, Vol. 33 (pp S1220-S1220)
Sprules AR, Latif NB, Brown JE, Gartland A & Wang N (2021) Abstract 2904: Mechanical loading induced osteogenic response does not interfere with the colonization of breast cancer in bone. Cancer Research, Vol. 81(13_Supplement) (pp 2904-2904)
Al-janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) Abstract 2797: Changes in the phenotype of macrophages and CD8+ T Cells in the perivascular niche of prostate tumours following androgen deprivation. Cancer Research, Vol. 81(13_Supplement) (pp 2797-2797)
Sprules AR, Latif NB, Brown JE, Gartland A & Wang N (2021) Mechanical loading induced osteogenic response does not interfere with the colonization of breast cancer in bone.. CANCER RESEARCH, Vol. 81(13)
Al-Janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) Changes in the phenotype of macrophages and CD8+T Cells in the perivascular niche of prostate tumours following androgen deprivation.. CANCER RESEARCH, Vol. 81(13)
Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. CANCER RESEARCH, Vol. 81(4)
Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Poster Session Abstracts
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
Brown JE, Handforth C, Walsh J, Pezaro C, Sydes MR, Clarke NW, James ND & McCloskey E (2019) 857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. Annals of Oncology, Vol. 30(Suppl 5) (pp v334-v335). Barcelona, Spain, 27 September 2019 - 1 October 2019.
Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment. Poster Session Abstracts
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Abstract B13: Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence. Early Clinical Opportunities
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.. MOLECULAR CANCER RESEARCH, Vol. 16(8) (pp 68-69)
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S , Ruiz Cabrero I et al (2018) Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. General Session Abstracts
Kelly-Morland C, Zhong J, Goh V, Wah T, Ralph C, Thistlethwaite F, Patel P, Nathan P, Eisen T, Gregory W , McParland L et al (2017) Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial. ANNALS OF ONCOLOGY, Vol. 28
Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S, Boleti E, Bahl A , Fife K et al (2017) Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma?. Journal of Clinical Oncology, Vol. 35(15_suppl) (pp e16061-e16061)
Trainor S, Wah T, Ralph C, McParland L, Gregory W, Brown J, Best E, Handforth C, Chan K, Cook H , Hiley V et al (2017) The Practicalities Involved and Lessons Learned in the Transition from Central to Local Radiology Reporting in the Context of a Seamless Phase II/III Clinical Trial. Clinical Oncology, Vol. 29(3) (pp e89-e89)
Smith MR, Brown JE, Fizazi K, Klotz L, Marx GM, Wang H, Warner D & Lipton A (2015) Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).. Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 267-267)
Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD, Rini BI, Lin W , O'Keeffe B et al (2014) A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 4525-4525)
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) Abstract P2-11-07: Proteins predictive of bone metastasis development in breast cancer patients. Poster Session Abstracts
Von Moos R, Fallowfield L, Cleeland C, Patrick D, Body JJ, Brown JE, Marx G, Zhou Y, Balakumaran A & Qian YI (2013) Effect of skeletal-related events on pain interference in patients with solid tumors and bone metastases. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S269-S269)
Von Moos R, Stopeck A, Fizazi K, Cleeland C, Brown JE, Oudard S, Costa L, Wang H & Braun A (2013) Skeletal-related events in patients with solid tumors receiving denosumab or zoledronic acid by baseline pain status: Results from three phase 3 trials. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S268-S268)
Brown J, Saad F, Stopeck A, Fizazi K, Henry D, Diel I, De Boer R, Wang H & Braun A (2013) Risk factors for developing osteonecrosis of the jaw (ONJ) in patients receiving denosumab or zoledronic acid for bone metastases: Results from three phase 3 trials. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S268-S269)
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
Fallowfield L, Cleeland CS, Von Moos R, Patrick D, Body J-J, Egerdie B, Stopeck A, Brown JE, Marx GM, Palazzo F , Damyanov DI et al (2013) Impact of skeletal-related events on pain and analgesic use in patients with solid tumors and bone metastases.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
Lipton A, Saad F, Van Poznak CH, Brown JE, Stopeck A, Fizazi K, Henry DH, Shore ND, Diel IJ, Tonkin KS , De Boer RH et al (2013) Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
Costa L, Fizazi K, Saad F, Brown JE, Von Moos R, Oudard S, Sternberg CN, Ganju V, Miller K, Wang H , Maniar T et al (2013) Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
Kueppers F, Fizazi K, Brown J, Carducci M, Shore N, Sieber P, Karsh L, Wei R & Goessl C (2013) 2-year open-label extension phase results from the pivotal phase 3 study of denosumab in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with denosumab or zoledronic acid. BJU INTERNATIONAL, Vol. 111 (pp 91-92)
Fizazi K, Brown JE, Carducci M, Shore ND, Sieber P, Kueppers F, Karsh L, Wei R & Goessl C (2012) DENOSUMAB IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DENOSUMAB OR ZOLEDRONIC ACID: 2-YEAR OPEN-LABEL EXTENSION PHASE RESULTS FROM THE PIVOTAL PHASE 3 STUDY. ANNALS OF ONCOLOGY, Vol. 23 (pp 309-309)
Matza LS, Cong Z, Chung K, Stopeck A, Tonkin KS, Brown JE, Braun AH, Van Brunt K & McDaniel K (2012) Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Fizazi K, Massard C, Smith MR, Rader ME, Brown JE, Milecki P, Shore ND, Oudard S, Karsh LI, Carducci MA , Damiao R et al (2012) Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Body J-J, Von Moos R, Saad F, Richardson GE, Brown JE, Lipton A, Fizazi K, Ying W, Goessl CD & Richhariya A (2012) Health resource utilization and patient burden associated with SREs in a randomized controlled trial setting. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Stopeck AT, Richardson G, Siena S, Lipton A, Brown J, Fizazi K, Henry D, Saad F, Ke C & Braun A (2012) DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES. EUROPEAN JOURNAL OF CANCER, Vol. 48 (pp S8-S8)
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Saad F, Yardley D, Maroto P, Ke C & Jun S (2011) Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid - Combined Analysis From 3 Registrational Trials. EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S240-S240)
Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22
Wood SL, Westbrook JA, Peng J, Selby PJ & Brown JE (2011) Development of a targeted strategy for enrichment and detection of calcium-binding proteins as potential biomarkers for bone metastases in breast cancer. BONE, Vol. 48(1) (pp S50-S51)
Brown J, Carducci M, Fizazi K, Smith M, Damiao DR, Karsh L, Milecki P, Wang H, Dansey R & Goessl C (2011) Denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer: Results from a phase 3 randomized trial. BONE, Vol. 48(1) (pp S16-S16)
Brown JE, Barrios CH, Diel IJ, Facon T, Fizazi K, Ibrahim T, Saad F, Senecal F, Stemmer SM, Stopeck A , Takahashi S et al (2011) Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. BONE, Vol. 48(1) (pp S18-S19)
Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) Towards biomarkers of bone-metastasis using cellular proteomics. BONE, Vol. 48(1) (pp S33-S33)
Woodward EJ, Brown JE, Barnfield MC, Taylor J, Blake GM, Fogelman I, Turner LA, Thorpe H, Dodwell D, Joffe JK & Coleman RE (2011) Bone health in breast cancer survivors following adjuvant bisphosphonate therapy: AZURE quantitative bone scan sub-study. BONE, Vol. 48(1) (pp S29-S29)
Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2011) Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefits from zoledronic acid. BONE, Vol. 48(1) (pp S20-S21)
Coleman RE, Woodward EJ, Brown JE, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE-BIG 01-04) for women with stage II/III breast cancer. BONE, Vol. 48(1) (pp S29-S29)
Michaelson D, Kpamegan EE, Perez JR & Brown J (2010) ZOLEDRONIC ACID (ZOL) REDUCES THE INCIDENCE OF SKELETAL-RELATED EVENT (SRES) AND MAY IMPROVE SURVIVAL IN PATIENTS WITH BONE METASTASES (METS) FROM RENAL CELL CARCINOMA (RCC): A RETROSPECTIVE INTEGRATED ANALYSIS. ANNALS OF ONCOLOGY, Vol. 21 (pp 287-287)
Brown J, Lipton A, Cook R, Michaelson D, Coleman R & Saad F (2010) Correlations between N-telopeptide of type I collagen with survival and fractures in patients with metastatic bone disease from renal cell carcinoma. BONE, Vol. 47 (pp S312-S312)
Costa L, Cook R, Body J, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) Zoledronic Acid Treatment Delays Disease Progression and Improves Survival in Patients With Bone Metastases From Solid Tumors and Elevated Levels of Bone Resorption. BONE, Vol. 47 (pp S302-S303)
Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) Possible Survival Benefits From Zoledronic Acid Treatment in Patients With Bone Metastases From Solid Tumors and Poor Prognostic Features. BONE, Vol. 47 (pp S311-S312)
Din OS, Brown JE, Ellis SP, Gutcher SA & Coleman RE (2010) The use of ultrasound densitometry as a screening tool for osteoporosis in early breast cancer. BONE, Vol. 47 (pp S311-S311)
Woodward EJ, Brown JE, Ellis SP, Gutcher S, Lester JE, Purohit O & Coleman RE (2010) Five year efficacy in cancer survivors of single dose zoledronic acid 4 mg in osteopaenia and annual dosing in osteoporosis. BONE, Vol. 47 (pp S310-S311)
Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
Brown J, Cook R, Hirsh V & Major P (2008) RISK FACTORS FOR SKELETAL-RELATED EVENT (SRES) IN ZOLEDRONIC ACID-TREATED PATIENTS WITH BONE METASTASES (METS) FROM NON-SMALL CELL LUNG CANCER (NSCLC). ANNALS OF ONCOLOGY, Vol. 19 (pp 275-275)
Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Coleman R, Brown J & Cook R (2008) Serum lactate dehydrogenase (LDH) is a significant prognostic variable for survival in patients with metastatic breast cancer - a multivariate analysis. EJC SUPPLEMENTS, Vol. 6(7) (pp 189-189)
Clarke K, Jagdev S, Newsham A, Lister J, Hayward K, Sastry K, Selby P & Brown J (2008) Bony metastases in renal cell carcinoma - An audit of patterns of disease and bisphosphonate use in patients treated in Leeds, UK. CANCER TREATMENT REVIEWS, Vol. 34 (pp S81-S82)
Kandukurti K, Zekri J, Marples M & Brown J (2008) Skeletal metastases in malignant melanoma. CANCER TREATMENT REVIEWS, Vol. 34 (pp S78-S78)
Brown J, Cook R & Coleman R (2008) Prognostic variables for occurrence of skeletal-related events (SREs) in patients with breast cancer metastatic to bone: A multivariate analysis. CANCER TREATMENT REVIEWS, Vol. 34 (pp S79-S79)
Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the AIRIBON study. CANCER TREATMENT REVIEWS, Vol. 34 (pp S51-S51)
Coleman R, Brown J & Cook R (2008) Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC). CANCER TREATMENT REVIEWS, Vol. 34 (pp S78-S79)
Hirsh V, Major P, Lipton A, Cook R, Langer C, Smith M, Brown J & Coleman R (2008) N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo. CANCER TREATMENT REVIEWS, Vol. 34 (pp S85-S85)
Vasudev NS, Brown JE, Brown SR, Cocks K, O'Donnell D, Patel PM, Harnden P, Banks RE & Selby PJ (2007) Preoperative sodium concentration as a possible predictor of survival in patients with renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) Normalization of bone markers and improved survival during zoledronic acid therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Lester J, Horsman J, Purohit OP, Brown JE & Coleman RE (2006) Bone resorption marker directed therapy for metastatic bone disease. BONE, Vol. 38(3) (pp S79-S79)
Lester JE, Penty L, Brown JE, Radstone C, Purohit OP & Coleman RE (2006) Characteristics and toxicity profile of patients receiving more than 2 years treatment with bisphosphonates for bone metastases from breast cancer. BONE, Vol. 38(3) (pp S79-S80)
Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O & Coleman RE (2006) For how long can a single infusion of zoledronic acid suppress bone resorption in patients with cancer treatment induced bone loss (CTIBL)?. BONE, Vol. 38(3) (pp S70-S70)
Lester JE, Gutcher SA, Ellis S, Thorpe R, Horsman J, Brown JE, Purohit OP, Dodwell D & Coleman RE (2006) The ARIBON study: Reversal of anastrozole (Arimidex) induced bone loss with oral monthly ibandronate (Bondronat) treatment during adjuvant therapy for breast cancer.. CANCER TREATMENT REVIEWS, Vol. 32 (pp S48-S49)
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O & Coleman RE (2006) Infrequent zoledronic acid produces sustained increases in bone mineral density (BMD) in patients with cancer treatment induced bone loss (CTIBL). CANCER TREATMENT REVIEWS, Vol. 32 (pp S19-S19)
Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40)
Lipton A, Coleman RE, Major P, Brown JE, Lee KA, Smith M, Saad F, Chen YM, Hei YJ & Cook R (2005) Baseline N-telopeptide levels correlate with risk of skeletal morbidity in patients with multiple myeloma during zoledronic acid therapy.. BLOOD, Vol. 106(11) (pp 964A-965A)
Cook RJ, Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Chen YM & Hei YJ (2005) Prognostic significance of biochemical markers of bone metabolism in patients with bone lesions from multiple myeloma (MM).. BLOOD, Vol. 106(11) (pp 335B-335B)
Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit OP, Hancock B & Coleman R (2005) Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 734S-734S)
Brown JE, Ellis SP, Gutcher SA, Purohit OP, Turner L, Neville-Webbe HL & Coleman RE (2005) Using bone turnover markers to direct bisphosphonate therapy: Is this a feasible approach?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S30-S30)
Lester JE, Brown JE, Ellis SP, Gutcher S, Horsman JM & Coleman RE (2005) The use of point of care devices for the monitoring of urinary NTX levels in metastatic breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S52-S53)
Brown JE, Ellis SP, Silcock P, Gutcher SA, Radstone C, Blumsohn A, Hancock BW, Hatton MQ & Coleman RE (2005) Do long-term cancer survivors, treated for testicular cancer or lymphoma, suffer chemotherapy-induced bone loss?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S46-S46)
Ellis SP, Brown JE, Everard JE, Neville-Webbe HL, Hancock BW & Coleman RE (2005) A study to determine whether the bisphosphonate zoledronic acid can be shown to exert a direct anti tumour effect in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S48-S49)
Ellis SP, Brown JE, Gutcher SA, Hancock BW, Hatton MQ, Rigby AS & Coleman RE (2004) An investigation of the long-term effects of chemotherapy on bone in male long-term cancer survivors. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1587-1587)
Cook RJ, Coleman RE, Saad F, Smith M, Lipton A, Lee KA, Brown JE, Zheng M, Hei YJ & Major P (2004) The predictive value of bone resorption and formation markers in patients with prostate cancer metastatic to bone. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
Brown JE, Cook RJ, Major P, Lipton A, Lee KA, Zheng M, Hei YJ & Coleman RE (2004) The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
Brown JE, Ellis S, Gutcher S, Lester JE, Turner L, Purohit OP, Hancock BW & Coleman RE (2004) Effect of an annual infusion of zoledronic acid on bone mineral density in cancer survivors following antineoplastic therapy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
Brown JE, McCloskey E, Dewar JA, Body JJ, Cameron DA, Purohit OPK, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 743S-743S)
Brown JE (2004) Prediction of skeletal complications in metastatic bone disease and strategies for management of treatment-induced bone loss. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S20-S20)
Brown J, Lester J, Ellis S, Gutcher S, Turner L, Purohit O, Hancock B & Coleman R (2004) Bone loss in long term cancer survivors. A pilot study to evaluate the effect of annual intravenous zoledronic acid on bone mineral density (BMD) and bone turnover markers. BONE, Vol. 34 (pp S93-S93)
Goodhart LM, Brown JE, Ellis S, Gutcher S, Purohit OP & Coleman RE (2003) Development of a touch screen questionnaire approach for measurement of pain assessment scales in cancer patients with bone metastasis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S67-S67)
Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate therapy in metastatic bone disease. BRIT J CANCER, Vol. 86 (pp S19-S19)
Brown JE, Ellis S, Gutcher S, Thompson C, Purohit OP & Coleman RE (2002) Relationship between bone resorption and skeletal events in metastatic done disease. BONE, Vol. 30(3) (pp 47S-47S)
Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate treatment. A pilot study to determine feasibility. BONE, Vol. 30(3) (pp 47S-47S)

Reports

Brown J (2023) Implementing frailty assessment and management in oncology services
Brown J (2022) Expert Panel: evaluation of the Government’s commitments in the area of cancer services in England View this article in WRRO

Other

Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.

Preprints

Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy, Cold Spring Harbor Laboratory.
Huang Q, Mitchell C, Theodoulou E, Lee A & Brown J (2024) Fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework, Research Square Platform LLC.
() Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study, Cold Spring Harbor Laboratory.
Reale S, Turner R, Sutton E, Taylor S, Bourke L, Morrissey D, Brown J, Rosario D, Steed L & NA OBOTSTAMINAC-I () Towards Implementing Exercise into the Prostate Cancer Care Pathway: Development of a Theory and Evidence-Based Intervention to Train Community-Based Exercise Professionals to Support Change in Patient Exercise Behaviour, Research Square Platform LLC.
Reale S, Turner R, Sutton E, Steed L, Taylor S, Morrissey D, Doherty P, Greenfield D, Collinson M, Hewison J , Brown J et al () Embedding Supervised Exercise Training for Men on Androgen Deprivation Therapy Into Standard Prostate Cancer Care: A Feasibility and Acceptability Study, Research Square Platform LLC.
Turner R, Arden M, Reale S, Sutton E, Taylor S, Bourke L, Greenfield D, Morrissey D, Brown J, Doherty P , Rosario D et al () Towards Implementing Exercise Into the Prostate Cancer Care Pathway: Development of a Theory and Evidence-Based Intervention to Change Healthcare Professional Behaviour, Research Square Platform LLC.

Research group

Associated Staff

Sarah Williams - YCR Support for E-IMMUNE
Carly Fisher - PA
Dr Steven Wood, Senior Research Associate
Maria Oliva, Research Assistant
Dr Margaret Paggiosi
Dr Jo Bird
Kate Fryer
Dr Elisavet Theodoulou, Clinical Research Fellow
Dr Rebecca Andrews, Clinical Research Fellow (Dr Andrew Chantry, main Clinical Supervisor)
Dr Qizhi Huang
Sophie Williams

Teaching activities: Janet has been engaged in many aspects of medical teaching including examining at undergraduate and postgraduate levels, and recently been personal tutor for many medical students, educational supervisor for 2 SpRs, supervisor for 5 Clinical PhD Fellows, 2 Clinical Lecturers, 4 ACFs, 4 SHOs, 2 BMedSci and 6 MSc students and 3 research nurses.

Principal recent professional activities and memberships

Appointed National Cancer Expert (2021-22) to the Expert Panel of the Parliamentary Health & Social Care Select Committee, to assess Government performance in meeting its cancer targets
Since 2024, South Yorkshire Director of Clinical Academic Training across all medical specialties
Since 2020, appointed to the MHRA National Oncology/Haematology Expert Advisory Group to advise on safety, efficacy and approval of medicines in UK, participating in licensing decisions on more than 50 drugs.
Since 2020, Clinical Lead for NICE appraisals of specific cancer drugs, advising on clinical need and value:- 2020-21, Alpelisib, a breast cancer drug from which 3,500 UK NHS patients are now benefiting.- 2022 radioligand targeted therapy in advanced prostate cancer, with 177Lu PSMA.
Since 2022, ED&I lead for MRC PhD studentships for 240 students at 5 northern Universities, embedding ED&I in the appointments process and providing support to appointees.
Since 2020, as a Disability Champion, she led disability initiatives, including a leading role in establishing the University of Sheffield Disability Network (Co-chair 2020-22), linking with NHS disability services.
Ongoing. Service on various UK and global Company Advisory Boards